Dipeptidyl Peptidase IV Inhibition in Animal Models of Diabetes

  • J. Andrew Pospisilik
  • Jan A. Ehses
  • Timothy Doty
  • Christopher H.S. McIntosh
  • Hans-Ulrich Demuth
  • Raymond A. Pedersohn
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 524)


Glucose Tolerance Gastric Inhibitory Polypeptide Dipeptidyl Peptidase Improve Glucose Tolerance Insulin Secretory Capacity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mentlein, R.: 1999. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept 85: 9–24PubMedCrossRefGoogle Scholar
  2. 2.
    Lambeir, A.-M., Durinx, C, Proost, P., Van Damme, J., Scharpe, S., De Meester, I.: 2001. Kinetic Study of the Processing by Dipeptidyl-Peptidase IV/CD26 of Neuropeptides Involved in Insulin Secretion. FEBS Lett 507: 327–30PubMedCrossRefGoogle Scholar
  3. 3.
    Pospisilik, J.A., Hinke, S.A., Pederson, R.A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U., Mclntosh, C.H., Demuth, H.-U.: 2001. Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul Pept 96: 133–41PubMedCrossRefGoogle Scholar
  4. 4.
    Kieffer, T.J., Habener, J.F.: 1999. The glucagon-like peptides. Endocr Rev 20: 876–913PubMedCrossRefGoogle Scholar
  5. 5.
    Ehses, J., Casilla, V., Pospisilik, J., Doty, T., Demuth, H.-U., Pederson, R., McIntosh, C.: 2002. Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulates Cell Growth and Promotes Survival of INS-1 Cells (Abstract). Diabetes 51: A339Google Scholar
  6. 6.
    Perry, T., Haughey, N.J., Mattson, M.P., Egan, J.M., Greig, N.H.: 2002. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302: 881–8PubMedCrossRefGoogle Scholar
  7. 7.
    Kieffer, T.J., McIntosh, C.H., Pederson, R.A.: 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585–96PubMedCrossRefGoogle Scholar
  8. 8.
    Pauly, R., Demuth, H.-U., Rosche, F., Schmidt, J., White, H., McIntosh, C., Pederson, R.: 1996. Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance. Regul Pept (abstract) 64: 148Google Scholar
  9. 9.
    Pauly, R.P., Demuth, H.U., Rosche, F., Schmidt, J., White, H.A., Lynn, F., McIntosh, C.H., Pederson, R.A.: 1999. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 48: 385–9PubMedCrossRefGoogle Scholar
  10. 10.
    Pederson, R.A., White, H.A., Schlenzig, D., Pauly, R.P., McIntosh, C.H., Demuth, H.U.: 1998. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47: 1253–8PubMedGoogle Scholar
  11. 11.
    Holst, J.J., Deacon, C.F.: 1998. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 Diabetes. Diabetes 47: 1663–70PubMedGoogle Scholar
  12. 12.
    Balkan, B., Kwasnik, L., Miserendino, R., Hoist, J.J., Li, X.: 1999. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42: 1324–31PubMedCrossRefGoogle Scholar
  13. 13.
    Deacon, C.F., Nauck, M.A., Meier, J., Hucking, K., Holst, J.J.: 2000. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85: 3575–81PubMedCrossRefGoogle Scholar
  14. 14.
    Pospisilik, J., Stafford, S., Demuth, H.-U., Brownsey, R., Parkhouse, W., Finegood, D., McIntosh, C., Pederson, R.: 2002. Long-term treatment with the DP IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and b-cell glucose responsiveness in VDF (fa/fa) Zucker Rats. Diabetes 51(4): 943–50.PubMedGoogle Scholar
  15. 15.
    Ahren, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Bavenholm, P., Efendic, S., Eriksson, J., Dickinson, S., Holmes, D.: 2002. Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes. Diabetes Care 25: 869–75PubMedGoogle Scholar
  16. 16.
    Sudre, B., Broqua, P., White, R., Ashworth, D., Evans, D., Haigh, R., Junien, J.-L., Aubert, M.: 2002. Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats. Diabetes 51: 1461–69PubMedGoogle Scholar
  17. 17.
    Pospisilik, J.A., Stafford, S.G., Demuth, H.U., McIntosh, C.H., Pederson, R.A.: 2002. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 51: 2677–83PubMedGoogle Scholar
  18. 18.
    Gutniak, M., Orskov, C., Holst, J.J., Ahren, B., Efendic, S.: 1992. Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316–22PubMedCrossRefGoogle Scholar
  19. 19.
    Dupre, J., Behme, M.T., Hramiak, I.M., McFarlane, P., Williamson, M.P., Zabel, P., McDonald, T.J.: 1995. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44: 626–30PubMedGoogle Scholar
  20. 20.
    De Meester, I., Korom, S., Van Damme, J., Scharpe, S.: 1999. CD26, let it cut or cut it down. Immunol Today 20: 367–75PubMedGoogle Scholar
  21. 21.
    Steinbrecher, A., Reinhold, D., Quigley, L., Gado, A., Tresser, N., Izikson, L., Born, I., Faust, J., Neubert, K., Martin, R., Ansorge, S., Brocke, S.: 2001. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 166: 2041–8PubMedGoogle Scholar
  22. 22.
    Pospisilik, J., Martin, J., Doty, T., Ehses, J., Pamir, N., Lynn, F., Piteau, S., Demuth, H.-U., McIntosh, C., Pederson, R.: 2002. Long-Term DP IV-Inhibitor Treatment Reduces the Severity of Streptozotocin-Induced Diabetic Rats Through Improvements in Glucose Tolerance, Islet Size and Function and Promotion of b-cell Survival (Abst.). Diabetes 51: A343Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • J. Andrew Pospisilik
    • 1
  • Jan A. Ehses
    • 1
  • Timothy Doty
    • 1
  • Christopher H.S. McIntosh
    • 1
  • Hans-Ulrich Demuth
    • 2
  • Raymond A. Pedersohn
    • 1
  1. 1.Department of PhysiologyUniversity of British ColumbiaVancouverCanada
  2. 2.Probiodrug Research, BiocenterHalle (Saale)Germany

Personalised recommendations